Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-88998377 in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT06470438Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of JNJ-88998377 in B-cell non-Hodgkin lymphoma (B-NHL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Adverse Events at 173 weeks and Dose Limiting Toxicities at 3 weeks. Started May 2024; status: active, not recruiting.
02
Drugs
JNJ-88998377
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT06470438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470438.